Benzinga's Top #PreMarket Losers
Caladrius Biosciences Inc (NASDAQ: CLBS) shares fell 32.08 percent to $0.72 in pre-market trading after the company reported that it will discontinue an ongoing Phase 3 study of CLBS20 as monotherapy for metastatic melanoma.
Epizyme Inc (NASDAQ: EPZM) shares fell 21.58 percent to $9.05 in pre-market trading after the company priced 13.33 million share offering at $9.00 per share.
Finish Line Inc (NASDAQ: FINL) shares fell 16.22 percent to $15.50 in pre-market trading after the company reported downbeat Q3 results and issued a weak earnings forecast. The company also reported that Sam Sato will succeed Glenn Lyon as CEO.
Akebia Therapeutics Inc (NASDAQ: AKBA) fell 9.38 percent to $8.70 in pre-market trading after the company priced 7.25 million share offering at $9.00 per share.
Atmel Corporation (NASDAQ: ATML) shares fell 8.28 percent to $7.86 in pre-market trading following Wednesday Bloomberg report that Microchip Technology Inc. (NASDAQ: MCHP) was reconsidering its $9.00 per share bid for Atmel.
KB Home (NYSE: KBH) shares fell 6.70 percent to $11.00 in pre-market trading after the company reported weaker-than-expected Q4 results.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.